Optimizing Immunogenicity of Lactobacillus as a Mucosal Vaccine Against HIV-1
优化乳酸菌作为 HIV-1 粘膜疫苗的免疫原性
基本信息
- 批准号:7494877
- 负责人:
- 金额:$ 22.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-02-15 至 2010-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAdjuvanticityAffectAgonistAnthrax diseaseAntibody FormationAntigensBacteriaBacterial GenomeBrucellaCell surfaceCellsCytoplasmCytosolDNA VaccinesDendritic CellsDevelopmentEngineeringFlagellinFoodFood PreservationGaggingGastrointestinal tract structureGenesHIVHIV vaccineHIV-1Helicobacter pyloriHumanHuman PapillomavirusImmuneImmune responseImmunizationIndigenousIntestinesInvestigationKineticsLactobacillusLocationLuciferasesMeasuresMediatingMethodsMolecular GeneticsMucosal Immune ResponsesMucous MembraneMusOrganismPreserved FoodsPreventionProbioticsProcessProductionPublic HealthPurposeRecombinant ProteinsRecombinantsResearchRotavirusSARS coronavirusSiteSurfaceT-LymphocyteTLR5 geneTetanus ToxinVaccinesVirus Replicationbioprocesscytokinefunctional genomicsgastrointestinalimmunogenicimmunogenicityin vivolactic acid bacteriamucosa-associated lymphoid tissuemucosal vaccinenoveloral vaccinepathogenprotein expressionresponsetransmission processvectorvector vaccine
项目摘要
DESCRIPTION (provided by applicant): Transmission of HIV-1 occurs predominately at mucosal surfaces and therefore a successful vaccine against HIV-1 must induce mucosal humoral and cellular immune responses. Lactobacillus is a very common commensal of the human gastrointestinal tract and is used commercially to process and preserve food, thus it is safe and unlikely to stimulate anti-vector immune responses. Futhermore, Lactobacillus is easy to manufacture, store and is highly manipulatable as the functional genomics are well understood. The well-known probiotic activities are due at least in part to the interaction of Lactobacillus with dendritic cells. Lactobacillus activates DC and stimulates cytokine production that leads to Th1 polarization of T cells. We have performed preliminary immunogenicity studies and demonstrated proof-of-principle for the use of Lactobacillus as a vaccine vector against HIV-1 but the vector must be further optimized to increase immunogenicity. In the studies proposed here, we will investigate the host/vector interaction to determine the kinetics and location of gastrointestinal colonization by recombinant Lactobacillus and whether recombinant protein expression affects the indigenous flora. The optimal subcellular location for HIV-1 antigen expression will be determined and a comprehensive assessment of mucosal and systemic humoral and cellular immune responses will be performed in mice. To further increase immunogenicity, flagellin will be expressed by the Lactobacillus as a method to increase innate immune activation in the gastrointestinal tract via TLR5 stimulation. Together these studies will determine whether Lactobacillus is worth further development as an oral vaccine vector against HIV-1. PUBLIC HEALTH RELEVANCE: The purpose of these studies is to develop a novel HIV vaccine strategy using Lactobacillus. A vaccine using lactobacilli would be safe, inexpensive to manufacture, and could be delivered orally. If successful, this strategy could have a significant impact on HIV prevention.
描述(由申请方提供):HIV-1的传播主要发生在粘膜表面,因此成功的HIV-1疫苗必须诱导粘膜体液和细胞免疫应答。乳酸杆菌是人类胃肠道的一种非常常见的寄生菌,商业上用于加工和保存食物,因此它是安全的,不太可能刺激抗载体免疫应答。乳酸杆菌易于生产、储存,并且由于功能基因组学已被充分理解,因此可高度操作。众所周知的益生菌活性至少部分是由于乳杆菌与树突细胞的相互作用。乳酸杆菌激活DC并刺激细胞因子产生,导致T细胞的Th 1极化。我们已经进行了初步的免疫原性研究,并证明了使用乳杆菌作为抗HIV-1疫苗载体的原理证明,但必须进一步优化该载体以提高免疫原性。在这里提出的研究中,我们将调查宿主/载体的相互作用,以确定动力学和重组乳酸杆菌的胃肠道定植的位置,以及重组蛋白的表达是否影响土著植物群。将确定HIV-1抗原表达的最佳亚细胞位置,并在小鼠中对粘膜和全身体液和细胞免疫应答进行全面评估。为了进一步增加免疫原性,鞭毛蛋白将由乳杆菌表达,作为通过TLR 5刺激增加胃肠道中先天免疫激活的方法。这些研究将共同确定乳杆菌是否值得进一步开发作为抗HIV-1的口服疫苗载体。公共卫生相关性:这些研究的目的是利用乳酸杆菌开发一种新的HIV疫苗策略。使用乳酸杆菌的疫苗是安全的,生产成本低,并且可以口服。如果成功,这一战略将对艾滋病毒预防产生重大影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gregg A Dean其他文献
Gregg A Dean的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gregg A Dean', 18)}}的其他基金
CSU Infectious Disease Research and Response Training Program
科罗拉多州立大学传染病研究和应对培训计划
- 批准号:
10657788 - 财政年份:2021
- 资助金额:
$ 22.28万 - 项目类别:
CSU Infectious Disease Research and Response Training Program
科罗拉多州立大学传染病研究和应对培训计划
- 批准号:
10490359 - 财政年份:2021
- 资助金额:
$ 22.28万 - 项目类别:
CSU Infectious Disease Research and Response Training Program
科罗拉多州立大学传染病研究和应对培训计划
- 批准号:
10268828 - 财政年份:2021
- 资助金额:
$ 22.28万 - 项目类别:
Oral Induction of Mucosal and Systemic Antibodies Against HIV-1 gp41 MPER
口服诱导抗 HIV-1 gp41 MPER 的粘膜和全身抗体
- 批准号:
8892070 - 财政年份:2014
- 资助金额:
$ 22.28万 - 项目类别:
Oral Induction of Mucosal and Systemic Antibodies Against HIV-1 gp41 MPER
口服诱导抗 HIV-1 gp41 MPER 的粘膜和全身抗体
- 批准号:
8790302 - 财政年份:2014
- 资助金额:
$ 22.28万 - 项目类别:
International Feline Retrovirus Research Symposium
国际猫逆转录病毒研究研讨会
- 批准号:
7927868 - 财政年份:2010
- 资助金额:
$ 22.28万 - 项目类别:
Recombinant Lactobacillus as an Oral Mucosal Vaccine Against HIV-1
重组乳杆菌作为抗 HIV-1 的口腔粘膜疫苗
- 批准号:
7932516 - 财政年份:2009
- 资助金额:
$ 22.28万 - 项目类别:
Comparative Medicine and Translational Research Training Program
比较医学和转化研究培训计划
- 批准号:
7900894 - 财政年份:2008
- 资助金额:
$ 22.28万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 22.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 22.28万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 22.28万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 22.28万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 22.28万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 22.28万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 22.28万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 22.28万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 22.28万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 22.28万 - 项目类别:














{{item.name}}会员




